【2017 CSCO】Speaking with Data, NextSeq of Annoroad Enables Cancer Gene Sequencing
2017.10.27

On September 26, 2017, the high-profile 2017 meeting of CSCO was held in Xiamen. With the gradual implementation of ‘precision medicine’ in China, cancer diagnosis and treatment has stepped into the age of individuation and precision medicine and NGS is the important technical means for promoting precision treatment. Then how can we find an excellent gene sequencing platform to enable cancer gene sequencing in China?

  


At Illumina's satellite meeting, Professor Xu Ling from Peking University First Hospital shared the research achievements based on the project of Research on Evaluation of Therapeutic Efficiency of the Application of circulating tumor DNA in Neoadjuvant Treatment of Breast Cancer jointly conducted with Annoroad earlier. The most advanced desktop high-throughput sequencing platform NextSeq 550AR developed by Annoroad and Illumina was used in the research in this project, and superb research data has been acquired. Based on the research data, Professor Xu Ling says that, compared with other sequencing platforms, Annoroad's NextSeq 550AR sequencing platform is more stable and accurate and more suitable for clinical cancer gene sequencing. The overall solution from sampling to results relying on this platform provides great convenience for clinical application research.  


The satellite meeting was presided over by Professor Wang Jie from Cancer Institute & Hospital, Chinese Academy of Medical Sciences. Professor Xu Ling from Peking University First Hospital, Professor Zhang Xuchao from Guangdong General Hospital, and Peng Junjie from Fudan Cancer Hospital delivered wonderful speeches to the participants on the achievements respectively in breast cancer, lung cancer, colorectal cancer, and molecular detecting technology. 


微信图片_20170928091832.jpg

Meeting Scene 


Research of the clinical applications of ctDNA detection technology in early-stage breast cancer screening


The participants paid high attention to breast cancer as it is the most common cancer occurring to women. Professor Xu Ling from Peking University First Hospital delivered to the participants a speech entitled The Exploratory Research of New Generation Sequencing Detection ctDNA in Early-stage Breast Cancer. She shared on site with the participants the research of the clinical applications of ctDNA detection technology in early-stage breast cancer screening.  


    Professor Xu Ling said that reports indicate that for protein diagnostic marker CA15-3 and circulating tumor cells in blood, ctDNA has higher sensitivity and specificity in detecting dynamic development of tumor. With ctDNA, we can predict earlier the dynamic development of tumor. And we find that the content of ctDNA in plasma is closely associated with prognosis. The higher the content is, the 5-year survival rate is lower. 

Based on this, Peking University First Hospital used advanced desktop high-throughput sequencing platform NextSeq 550AR gene sequencer developed by Annoroad and Illumina and jointly conducted the Research on Evaluation of Therapeutic Efficiency of the Application of Circulating Tumor DNA in Neoadjuvant Treatment of Breast Cancer. The researchers searched for related genes based on NGS, proved and investigated the clinical application value of ctDNA detection technology in breast cancer detection. 


One hundred cases in total have been included in the research in this project. The researchers have finished sample collection, storage, and registration of clinical, pathological, and follow-up data, and conducted four groups of pilot experiments. In pilot experiment 4, NGS detection exploratory research was conducted on 76 breast cancer cases and control (external control) was made against 32 healthy people samples. In accordance with the detection of 247 related genes such as ALK, BRAF, EGFR, ERBB2, KRAS, NRAS, MET, KIT and PIK3CA, there are 328,000 loci (bases) in total in the hotspot mutation region. The detection range of the research project includes mutation types in the gene coding region such as single nucleotide variation (SNV), small piece insertion/deletion (InDel), fusion gene (Fusion), and copy number variation (CNA). In total 319 mutations (SNP: 200, InDel: 119) are obtained by screening, covering 46 samples relating to 18 genes. The detection rate is 60.52% (46/76). Meanwhile, it is found in the experiment that the distribution of the mutation of 11 genes such as ERBB2 is non-randomized, but that they are distributed in hotspot regions. 


NextSeq 550AR high-throughput gene sequencing platform 


Professor Xu Ling says that NextSeq 550AR gene sequencing platform used in the research in the whole project is very stable and accurate, and is more suitable for clinical tumor gene sequencing, compared with other sequencing platforms. In addition, the overall solution from sampling to results relying on NextSeq 550AR sequencing platform provides great convenience for clinical application research.

 image.png

 NextSeq 550AR high-throughput gene sequencer 


In addition to cooperation in research projects with Peking University First Hospital, Annoroad has also cooperated with numerous well-known tumor hospitals and large general hospital both at home and abroad in research projects and acquired superb data. 


NextSeq 550AR is the new generation desktop high-throughput gene sequencer jointly developed by Annoroad and Illumina. The latest developed dual channel ‘Sequencing by Synthesis (SBS) technology and the classic ‘reversible end terminator’ patented technology are adopted for this sequencer. It has numerous advantages such as high throughput, great speed, accurate data, stable performance, and easy operation. Compared with the equipment commercially available so far, it has significant leading edge in data quality, stability, and batch sample processing capacity. Meanwhile, NextSeq 550AR has strong clinical and academic application scalability, and the kits development and registration of PGS, liquid biopsy, FFPE sequencing, genetic disease detection can be implemented on this sequencing platform.


Annoroad, as one of the first genetic testing technology application demonstration centers approved by the National Development and Reform Commission and one of the first pilot enterprises of high-throughput sequencing clinical application approved by the National Health and Family Planning Commission of PRC, has all the time been committed to R&D and innovation of the precise treatment technology.  At 2016 CSCO, Annoroad released the first ctDNA new technology GSP technology, which was matched with perfect quality control system at every detection link in order to ensure the accuracy of detection, providing precise and comprehensive detection and interpretation for clinic. 


分享:

Copyright © Annoroad Gene Technology 京ICP备12029022号-1